Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors

NCT04776629 is registered in ClinicalTrials.gov with Abcentra as lead sponsor.

NCT NCT04776629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Lead sponsor
Abcentra
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2021
Completion date
November 11, 2022
Enrollment
77 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cardiometabolic syndrome, coronary artery disease, inflammation, psoriasis